The Healthcare sector +0.4% is outperforming the weakness in the S&P 500 -0.04%.
News: SGNT +10% launches Vecuronium Bromide for injection, CYTK +3.4% announces Phase I and Phase IIa clinical trial results for Omecamtiv Mecarbil Published in the Journal Lancet, FURX +1.4% enters into loan agreement for up to $15 mln, UTHR +0.8% S.A.C. Capital reports a 3.6% passive stake in the co, ARRY -0.68% BVF Partners reports a 6% stake in the co, and CVM -5.7% announced that it has received and responded to a Warning Letter issued to the Co by the Division of Drug Advertising Marketing and Compliance.
Broker Research: NKTR +3.6% initiated with a Buy at MKM Partners, CERN +1.6%, upgraded at Cowen, SSRX +0.4% initiated iwth an Outperform at Cowen, HLS -0.9% initiated with a Buy at Mizuho.






